HomeProductsBioactive CompoundsCell CycleCDKRibociclib
Chemical structure of CAS 1211441-98-3

Ribociclib

CAS No.1211441-98-3
MDL No.MFCD27976795
MFC23H30N8O
MW434.50
InChI KeyRHXHGRAEPCAFML-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Ribociclib is a piperazine and a pyridine derivative.

CAS No.1211441-98-3
Product NameRibociclib

Biological Targets

CDK4·CDK6

Associated Conditions

fallopian tube cancer·dedifferentiated liposarcoma·neoplasm·myelofibrosis·liposarcoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 22, Issue 23 • 2016
PMID: 27542767PMC: PMC5621377DOI: 10.1158/1078-0432.CCR-16-1248

Molecular pathways: CDK4 inhibitors for cancer therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 20, Issue 13 • 2014
PMID: 24795392DOI: 10.1158/1078-0432.CCR-13-1551

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 19, Issue 22 • 2013
PMID: 24045179PMC: PMC3844928DOI: 10.1158/1078-0432.CCR-13-1675

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.

Cancer biology & therapy • Vol. 14, Issue 7 • 2013
PMID: 23792647PMC: PMC3742489DOI: 10.4161/cbt.24592

Documentation

Similar Products